According to a new report Global Pharmacogenomics Market, published by KBV research, The Global Pharmacogenomics Market size is expected to reach $9.9 billion by 2025, rising at a market growth of 8.8% CAGR during the forecast period.
The Hospitals and Clinics market dominated the Global Pharmacogenomics Market by End User in 2018, growing at a CAGR of 8.5 % during the forecast period. The Research Institutions market is expected to witness highest CAGR of 9.1% during (2019 - 2025).
The North America market dominated the Global Infectious Diseases Market by Region in 2018, growing at a CAGR of 9.1 % during the forecast period. The Europe market is expected to witness a CAGR of 9.3% during (2019 - 2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 11.2% during (2019 - 2025).
The Sequencing market in the Global Pharmacogenomics Market by Technology would grow at a CAGR of 8 % during the forecast period. The Polymerase Chain Reaction market is expected to witness a CAGR of 8.1% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/pharmacogenomics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
By Technology
By Application
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
